CTOs on the Move

Interior Health

www.interiorhealth.ca

 
With the help of our staff and physicians, Interior Health is proud to deliver high-quality health-care services to the communities and visitors of the Southern Interior of British Columbia. We strive to set new standards of excellence in the delivery of health services in the province of B.C. and our mission is to promote healthy lifestyles and provide needed health services in a timely, caring and efficient manner, to the highest professional and quality standards.
  • Number of Employees: 5K-10K
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Humacyte

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte`s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte`s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA`s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.

OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.

gloStream

gloStream Inc. is a Troy, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Union Printers Home

Union Printers Home is a Colorado Springs, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

International Society for Biomedical Research on Alcoholism

International Society for Biomedical Research on Alcoholism is a Denver, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.